HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MHY3200

PPARalpha agonist

Also Known As:

2-(4-(5-chlorobenzo(d)thiazol-2-yl)phenoxy)-2,2-difluoroacetic acid

Networked: 2 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - MHY3200: 2
- Sulfur Compounds: 278
  - Thiazoles: 392
    - MHY3200: 2
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Acetates: 4994
      - MHY3200: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - MHY3200: 2

Experts

1.	Chung, Hae Young: 2 articles (05/2021 - 08/2018)
2.	Kim, Dae Hyun: 2 articles (05/2021 - 08/2018)
3.	Kim, Min Jo: 2 articles (05/2021 - 08/2018)
4.	Moon, Hyung Ryong: 2 articles (05/2021 - 08/2018)
5.	Bang, EunJin: 1 article (05/2021)
6.	Chun, Pusoon: 1 article (05/2021)
7.	Noh, Sang Gyun: 1 article (05/2021)
8.	Yokozawa, Takako: 1 article (05/2021)
9.	Hyun, Min Kyung: 1 article (08/2018)
10.	Lee, A Kyoung: 1 article (08/2018)

Related Diseases

1.	Inflammation (Inflammations) 05/26/2021 - "Our results suggest that MHY3200 ameliorates age-associated renal inflammation by regulating NF-κB and FoxO1 via ROS/Akt signaling." 05/26/2021 - "PPARα Agonist, MHY3200, Alleviates Renal Inflammation during Aging via Regulating ROS/Akt/FoxO1 Signaling." 08/16/2018 - "Our results suggested that MHY3200 ameliorated HFD-induced hepatic lipid accumulation and inflammation, and improved insulin resistance through PPARα activation." 08/16/2018 - "This study investigated the effects of 2-(4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy)-2,2-difluoroacetic acid (MHY3200) on high-fat diet (HFD)-induced hepatic lipid accumulation and inflammation. "
2.	Insulin Resistance 08/16/2018 - "Our results suggested that MHY3200 ameliorated HFD-induced hepatic lipid accumulation and inflammation, and improved insulin resistance through PPARα activation."
3.	Non-alcoholic Fatty Liver Disease 08/16/2018 - "Hepatoprotective Effects of MHY3200 on High-Fat, Diet-Induced, Non-Alcoholic Fatty Liver Disease in Rats."
4.	Weight Gain 08/16/2018 - "No weight gain was detected when compared with HFD rats, and hepatic TG content was also attenuated by the administration of MHY3200. "
5.	Body Weight (Weight, Body) 05/26/2021 - "Young (7-month-old) and old (22-month-old) rats were treated with MHY3200 (1 mg/kg body weight/day or 3 mg/kg body weight/day) for two weeks. "

Related Drugs and Biologics

1.	Lipids
2.	difluoroacetic acid (difluoroacetate)